Clinical trial
A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
NCT02633033 is registered in ClinicalTrials.gov with Mallinckrodt as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse
- Lead sponsor
- Mallinckrodt
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 24, 2015
- Completion date
- May 9, 2019
- Enrollment
- 160 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.